CA2589966A1 - Novel diazabicyclononene derivative - Google Patents
Novel diazabicyclononene derivative Download PDFInfo
- Publication number
- CA2589966A1 CA2589966A1 CA002589966A CA2589966A CA2589966A1 CA 2589966 A1 CA2589966 A1 CA 2589966A1 CA 002589966 A CA002589966 A CA 002589966A CA 2589966 A CA2589966 A CA 2589966A CA 2589966 A1 CA2589966 A1 CA 2589966A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- renal
- mixture
- renin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- QDFXRVAOBHEBGJ-UHFFFAOYSA-N 3-(cyclononen-1-yl)-4,5,6,7,8,9-hexahydro-1h-diazonine Chemical class C1CCCCCCC=C1C1=NNCCCCCC1 QDFXRVAOBHEBGJ-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 73
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 41
- 239000002904 solvent Chemical class 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 230000036454 renin-angiotensin system Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 7
- 201000006370 kidney failure Diseases 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- SXZFQYPWEANJGQ-SKCUWOTOSA-N (1r,5s)-7-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-n-cyclopropyl-n-[(2,3-dichlorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide Chemical compound C=1([C@@]2([H])CNC[C@](N2)(CC=1C=1C=CC(CCCOC=2C(=C(F)C=CC=2F)Cl)=CC=1)[H])C(=O)N(C1CC1)CC1=CC=CC(Cl)=C1Cl SXZFQYPWEANJGQ-SKCUWOTOSA-N 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 3
- 208000006029 Cardiomegaly Diseases 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 206010063897 Renal ischaemia Diseases 0.000 claims description 3
- 230000009787 cardiac fibrosis Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 230000000877 morphologic effect Effects 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- KJYVKUQRRKDPAX-UHFFFAOYSA-N n-[(2,3-dichlorophenyl)methyl]cyclopropanamine Chemical compound ClC1=CC=CC(CNC2CC2)=C1Cl KJYVKUQRRKDPAX-UHFFFAOYSA-N 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 201000002793 renal fibrosis Diseases 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010020571 Hyperaldosteronism Diseases 0.000 claims description 2
- 206010038419 Renal colic Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 238000007675 cardiac surgery Methods 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004406 elevated intraocular pressure Effects 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 238000007631 vascular surgery Methods 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- 108090000783 Renin Proteins 0.000 abstract description 12
- 102100028255 Renin Human genes 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 239000003112 inhibitor Substances 0.000 abstract description 3
- YJTZZSKGEPHUTF-UHFFFAOYSA-N 3,9-diazabicyclo[3.3.1]non-4-ene Chemical class C1NC=C2CCCC1N2 YJTZZSKGEPHUTF-UHFFFAOYSA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 20
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 229910001868 water Inorganic materials 0.000 description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- 239000002461 renin inhibitor Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000012876 carrier material Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000010410 layer Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000008279 sol Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 229940086526 renin-inhibitors Drugs 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- -1 calcium antagonists Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 239000005541 ACE inhibitor Substances 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 5
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 5
- 230000004872 arterial blood pressure Effects 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004881 Angiotensinogen Human genes 0.000 description 3
- 108090001067 Angiotensinogen Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101000579218 Homo sapiens Renin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- SWJPEBQEEAHIGZ-UHFFFAOYSA-N 1,4-dibromobenzene Chemical compound BrC1=CC=C(Br)C=C1 SWJPEBQEEAHIGZ-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- IXIZSAAJTPZUBU-UHFFFAOYSA-N 2-chloro-3,6-difluorophenol Chemical compound OC1=C(F)C=CC(F)=C1Cl IXIZSAAJTPZUBU-UHFFFAOYSA-N 0.000 description 2
- 101150059573 AGTR1 gene Proteins 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- 102000003858 Chymases Human genes 0.000 description 2
- 108090000227 Chymases Proteins 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000004129 EU approved improving agent Substances 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 125000004799 bromophenyl group Chemical group 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LLMLNAVBOAMOEE-UHFFFAOYSA-N 2,3-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1Cl LLMLNAVBOAMOEE-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 101000988143 Antheraea pernyi Pheromone-binding protein 1 Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 101000732617 Homo sapiens Angiotensinogen Proteins 0.000 description 1
- 101001057135 Homo sapiens Melanoma-associated antigen H1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100027256 Melanoma-associated antigen H1 Human genes 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 238000006411 Negishi coupling reaction Methods 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- YYVFXSYQSOZCOQ-UHFFFAOYSA-N Oxyquinoline sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C[NH+]=C2C(O)=CC=CC2=C1.C1=C[NH+]=C2C(O)=CC=CC2=C1 YYVFXSYQSOZCOQ-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Chemical class 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000003119 guanylate cyclase activator Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000006197 hydroboration reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002810 primary assay Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000948 sympatholitic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000002348 vinylic group Chemical group 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The invention relates to a novel 3,9-diazabicyclo[3.3.1]nonene derivative and the enantiomers thereof and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing at least one compound of formula (I) or (I~) and especially their use as inhibitors of renin.
Description
Novel Diazabicyclononene Derivative The invention relates to novel compounds of the formula (I) and the enatiomer thereof of formula (I'). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing at least one compound of formula (I) or (I') and especially their use as renin inhibitors in cardiovascular events and renal insufficiency.
In the renin-angiotensin system (RAS) the biologically active angiotensin II
(Ang II) is generated by a two-step mechanism. The highly specific enzyme renin cleaves angiotensinogen to angiotensin I (Ang I), which is then further processed to Ang II by the less specific angiotensin-converting enzyme (ACE). Ang II is known to work on at least two receptor subtypes called AT1 and AT2. Whereas AT1 seems to transmit most of the known functions of Ang II, the role of AT2 is still unknown.
Modulation of the RAS represents a major advance in the treatment of cardiovascular diseases. ACE inhibitors and AT1 blockers have been accepted to treat hypertension (Waeber B. et al., "The renin-angiotensin system: role in experimental and human hypertension", in Birkenhager W. H., Reid J. L. (eds):
Hypertension, Amsterdam, Elsevier Science Publishing Co, 1986, 489-519;
Weber M. A., Am. J. Hypertens., 1992, 5, 247S). In addition, ACE inhibitors are used for renal protection (Rosenberg M. E. et al., Kidney International, 1994, 45, 403; Breyer J. A. et al., Kidney International, 1994, 45, S156), in the prevention of congestive heart failure (Vaughan D. E. et al., Cardiovasc. Res., 1994, 28, 159;
Fouad-Tarazi F. et al., Am. J. Med., 1988, 84 (Suppl. 3A), 83) and myocardial infarction (Pfeffer M. A. et al., N. Engl. J. Med., 1992, 327, 669).
The rationale to develop renin inhibitors is the specificity of renin (Kleinert H. D., Cardiovasc. Drugs, 1995, 9, 645). The only substrate known for renin is angiotensinogen, which can only be processed (under physiological conditions) by renin. In contrast, ACE can also cleave bradykinin besides Ang I and can be by-passed by chymase, a serine protease (Husain A., J. Hypertens., 1993, 11, 1155).
In patients inhibition of ACE thus leads to bradykinin accumulation causing cough (5-20%) and potentially life-threatening angioneurotic edema (0.1-0.2%) (Israili Z. H. et al., Annals of Internal Medicine, 1992, 117, 234). Chymase is not inhibited by ACE inhibitors. Therefore, the formation of Ang II is still possible in patients treated with ACE inhibitors. Blockade of the AT1 receptor (e.g. by losartan) on the other hand overexposes other AT-receptor subtypes (e.g. AT2) to Ang II, whose concentration is significantly increased by the blockade of AT1 receptors. In summary, renin inhibitors are expected to demonstrate a different pharmaceutical profile than ACE inhibitors and AT1 blockers with regard to efficacy in blocking the RAS and in safety aspects.
Only limited clinical experience (Azizi M. et al., J. Hypertens., 1994, 12, 419;
Neutel J. M. et al., Am. Heart, 1991, 122, 1094) has been created with renin inhibitors because of their insufficient oral activity due to their peptidomimetic character (Kleinert H. D., Cardiovasc. Drugs, 1995, 9, 645). The clinical development of several compounds has been stopped because of this problem together with the high cost of goods. Only one compound containing four chiral centers has entered clinical trials (Rahuel J. et al., Chem. Biol., 2000, 7, 493;
Mealy N. E., Drugs of the Future, 2001, 26, 1139). Thus, renin inhibitors with good oral bioavailability and long duration of action are required. Recently, the first non-peptide renin inhibitors were described which show high in vitro activity (Oefner C. et al., Chem. Biol., 1999, 6, 127; Patent Application WO 97/09311;
Marki H. P. et al., Il Farmaco, 2001, 56, 21). However, the development status of these compounds is not known.
The present invention relates to renin inhibitors of a non-peptidic nature and of low molecular weight. Described are orally active renin inhibitors of formula (I) and (I') which have a of long duration of action and which are active in indications beyond blood pressure regulation where the tissular renin-chymase system may be activated leading to pathophysiologically altered local functions such as renal, cardiac and vascular remodeling, atherosclerosis, and possibly restenosis.
In the renin-angiotensin system (RAS) the biologically active angiotensin II
(Ang II) is generated by a two-step mechanism. The highly specific enzyme renin cleaves angiotensinogen to angiotensin I (Ang I), which is then further processed to Ang II by the less specific angiotensin-converting enzyme (ACE). Ang II is known to work on at least two receptor subtypes called AT1 and AT2. Whereas AT1 seems to transmit most of the known functions of Ang II, the role of AT2 is still unknown.
Modulation of the RAS represents a major advance in the treatment of cardiovascular diseases. ACE inhibitors and AT1 blockers have been accepted to treat hypertension (Waeber B. et al., "The renin-angiotensin system: role in experimental and human hypertension", in Birkenhager W. H., Reid J. L. (eds):
Hypertension, Amsterdam, Elsevier Science Publishing Co, 1986, 489-519;
Weber M. A., Am. J. Hypertens., 1992, 5, 247S). In addition, ACE inhibitors are used for renal protection (Rosenberg M. E. et al., Kidney International, 1994, 45, 403; Breyer J. A. et al., Kidney International, 1994, 45, S156), in the prevention of congestive heart failure (Vaughan D. E. et al., Cardiovasc. Res., 1994, 28, 159;
Fouad-Tarazi F. et al., Am. J. Med., 1988, 84 (Suppl. 3A), 83) and myocardial infarction (Pfeffer M. A. et al., N. Engl. J. Med., 1992, 327, 669).
The rationale to develop renin inhibitors is the specificity of renin (Kleinert H. D., Cardiovasc. Drugs, 1995, 9, 645). The only substrate known for renin is angiotensinogen, which can only be processed (under physiological conditions) by renin. In contrast, ACE can also cleave bradykinin besides Ang I and can be by-passed by chymase, a serine protease (Husain A., J. Hypertens., 1993, 11, 1155).
In patients inhibition of ACE thus leads to bradykinin accumulation causing cough (5-20%) and potentially life-threatening angioneurotic edema (0.1-0.2%) (Israili Z. H. et al., Annals of Internal Medicine, 1992, 117, 234). Chymase is not inhibited by ACE inhibitors. Therefore, the formation of Ang II is still possible in patients treated with ACE inhibitors. Blockade of the AT1 receptor (e.g. by losartan) on the other hand overexposes other AT-receptor subtypes (e.g. AT2) to Ang II, whose concentration is significantly increased by the blockade of AT1 receptors. In summary, renin inhibitors are expected to demonstrate a different pharmaceutical profile than ACE inhibitors and AT1 blockers with regard to efficacy in blocking the RAS and in safety aspects.
Only limited clinical experience (Azizi M. et al., J. Hypertens., 1994, 12, 419;
Neutel J. M. et al., Am. Heart, 1991, 122, 1094) has been created with renin inhibitors because of their insufficient oral activity due to their peptidomimetic character (Kleinert H. D., Cardiovasc. Drugs, 1995, 9, 645). The clinical development of several compounds has been stopped because of this problem together with the high cost of goods. Only one compound containing four chiral centers has entered clinical trials (Rahuel J. et al., Chem. Biol., 2000, 7, 493;
Mealy N. E., Drugs of the Future, 2001, 26, 1139). Thus, renin inhibitors with good oral bioavailability and long duration of action are required. Recently, the first non-peptide renin inhibitors were described which show high in vitro activity (Oefner C. et al., Chem. Biol., 1999, 6, 127; Patent Application WO 97/09311;
Marki H. P. et al., Il Farmaco, 2001, 56, 21). However, the development status of these compounds is not known.
The present invention relates to renin inhibitors of a non-peptidic nature and of low molecular weight. Described are orally active renin inhibitors of formula (I) and (I') which have a of long duration of action and which are active in indications beyond blood pressure regulation where the tissular renin-chymase system may be activated leading to pathophysiologically altered local functions such as renal, cardiac and vascular remodeling, atherosclerosis, and possibly restenosis.
In particular, the present invention relates to a novel compound of the structural formula (I): (IR*, 5S*)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)-propyl]phenyl}-3,9-diazabicyclo[3.3.1 ]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide F CI )(?'~ F
(I) CI O
CI N 6~ 7 8 / ~ 5 N
(I) CI O
CI N 6~ 7 8 / ~ 5 N
H
and optically pure enantiomers or a mixture of enantiomers such as a racemate;
as well as pharmaceutically acceptable salts, solvent complexes and morphological forms thereof.
A preferred enantiomer is the one represented by formula (I'): (IR, 5S)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl} -3,9-diazabicyclo[3.3.1 ]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide C)!?"' F
F
(I') CI O
CI N
H H
N
H
The expression pharmaceutically acceptable salts encompasses either salts with inorganic acids or organic acids like hydrochloric or hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, and the like that are non toxic to living organisms.
The compounds of the formula (I) contain two inter-dependent asymmetric carbon atoms having the relative stereochemistry (IR*, 5S*) and may be prepared in form of the optically pure enantiomers (IR, 5S)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)-propyl]phenyl} -3,9-diazabicyclo[3.3.1 ]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide (i.e. compound of formula (I') which is preferred) and (IS, 5R)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)-propyl]phenyl} -3,9-diazabicyclo[3.3.1 ]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide, or as a mixture of the two enantiomers such as a racemate. The present invention encompasses all these forms. Mixtures may be separated in a manner known per se, i.e. by column chromatography, thin layer chromatography, HPLC, crystallization, or resolution.
Especially a resolution of compound 3 (vide infra) is possible, using tartaric acid.
The use of n-(-)-tartaric acid will lead to the desired enantiomer.
The compounds of formula (I) and (I') are useful for the treatment and/or prophylaxis of diseases associated with a dysregulation of the renin-angiotensin system, in particular diseases such as or related to hypertension, congestive heart failure, pulmonary hypertension, renal insufficiency, renal ischemia, renal failure, renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis, myocardial ischemia, cardiomyopathy, glomerulonephritis, renal colic, complications resulting from diabetes such as nephropathy, vasculopathy and neuropathy, glaucoma, elevated intra-ocular pressure, atherosclerosis, restenosis post angioplasty, complications following vascular or cardiac surgery, erectile dysfunction, hyperaldosteronism, lung fibrosis, scleroderma, anxiety, cognitive disorders, complications of treatments with immunosuppressive agents, and other diseases known to be related to the renin-angiotensin system.
The compounds of formula (I) and (I') are especially useful for the treatment and/or prophylaxis of hypertension, congestive heart failure, pulmonary hypertension, renal insufficiency, renal ischemia, renal failure, renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis, myocardial ischemia, 5 cardiomyopathy, complications resulting from diabetes such as nephropathy, vasculopathy and neuropathy.
In one embodiment, the invention relates to a method for the treatment or prophylaxis of diseases, which are associated with a dysregulation of the renin-angiotensin system, in particular to a method for the treatment or prophylaxis of the above-mentioned diseases, said methods comprising administering to a patient a pharmaceutically active amount of a compound of formula (I) or (I').
A further aspect of the present invention relates to pharmaceutical compositions comprising a compound of formula (I) or (I') and a pharmaceutically acceptable carrier material. These pharmaceutical compositions may be used for the treatment and/or prophylaxis of the above-mentioned diseases. The pharmaceutical compositions can be used for enteral, parenteral, or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils.
The invention also relates to the use of a compound of formula (I) or (I') for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of the above-mentioned diseases.
The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Mark Gibson, Editor, Pharmaceutical Preformulation and Formulation, IHS Health Group, Englewood, CO, USA, 2001; Remington, The Science and Practice of Pharmacy, 20th Edition, Philadelphia College of Pharmacy and Science) by bringing the described compounds of formula (I) or (I') or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers are, however, required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injections are, for example, water, alcohols, polyols, glycerols and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffms, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavor-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
The dosage of compounds of formula (I) and (I') can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case.
In a preferred embodiment, this amount is comprised between 2 mg and 1000 mg per day.
and optically pure enantiomers or a mixture of enantiomers such as a racemate;
as well as pharmaceutically acceptable salts, solvent complexes and morphological forms thereof.
A preferred enantiomer is the one represented by formula (I'): (IR, 5S)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl} -3,9-diazabicyclo[3.3.1 ]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide C)!?"' F
F
(I') CI O
CI N
H H
N
H
The expression pharmaceutically acceptable salts encompasses either salts with inorganic acids or organic acids like hydrochloric or hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, and the like that are non toxic to living organisms.
The compounds of the formula (I) contain two inter-dependent asymmetric carbon atoms having the relative stereochemistry (IR*, 5S*) and may be prepared in form of the optically pure enantiomers (IR, 5S)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)-propyl]phenyl} -3,9-diazabicyclo[3.3.1 ]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide (i.e. compound of formula (I') which is preferred) and (IS, 5R)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)-propyl]phenyl} -3,9-diazabicyclo[3.3.1 ]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide, or as a mixture of the two enantiomers such as a racemate. The present invention encompasses all these forms. Mixtures may be separated in a manner known per se, i.e. by column chromatography, thin layer chromatography, HPLC, crystallization, or resolution.
Especially a resolution of compound 3 (vide infra) is possible, using tartaric acid.
The use of n-(-)-tartaric acid will lead to the desired enantiomer.
The compounds of formula (I) and (I') are useful for the treatment and/or prophylaxis of diseases associated with a dysregulation of the renin-angiotensin system, in particular diseases such as or related to hypertension, congestive heart failure, pulmonary hypertension, renal insufficiency, renal ischemia, renal failure, renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis, myocardial ischemia, cardiomyopathy, glomerulonephritis, renal colic, complications resulting from diabetes such as nephropathy, vasculopathy and neuropathy, glaucoma, elevated intra-ocular pressure, atherosclerosis, restenosis post angioplasty, complications following vascular or cardiac surgery, erectile dysfunction, hyperaldosteronism, lung fibrosis, scleroderma, anxiety, cognitive disorders, complications of treatments with immunosuppressive agents, and other diseases known to be related to the renin-angiotensin system.
The compounds of formula (I) and (I') are especially useful for the treatment and/or prophylaxis of hypertension, congestive heart failure, pulmonary hypertension, renal insufficiency, renal ischemia, renal failure, renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis, myocardial ischemia, 5 cardiomyopathy, complications resulting from diabetes such as nephropathy, vasculopathy and neuropathy.
In one embodiment, the invention relates to a method for the treatment or prophylaxis of diseases, which are associated with a dysregulation of the renin-angiotensin system, in particular to a method for the treatment or prophylaxis of the above-mentioned diseases, said methods comprising administering to a patient a pharmaceutically active amount of a compound of formula (I) or (I').
A further aspect of the present invention relates to pharmaceutical compositions comprising a compound of formula (I) or (I') and a pharmaceutically acceptable carrier material. These pharmaceutical compositions may be used for the treatment and/or prophylaxis of the above-mentioned diseases. The pharmaceutical compositions can be used for enteral, parenteral, or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils.
The invention also relates to the use of a compound of formula (I) or (I') for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of the above-mentioned diseases.
The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Mark Gibson, Editor, Pharmaceutical Preformulation and Formulation, IHS Health Group, Englewood, CO, USA, 2001; Remington, The Science and Practice of Pharmacy, 20th Edition, Philadelphia College of Pharmacy and Science) by bringing the described compounds of formula (I) or (I') or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers are, however, required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injections are, for example, water, alcohols, polyols, glycerols and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffms, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavor-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
The dosage of compounds of formula (I) and (I') can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case.
In a preferred embodiment, this amount is comprised between 2 mg and 1000 mg per day.
In a particularly preferred embodiment, this amount is comprised between 1 mg and 500 mg per day.
In a more particularly preferred embodiment, this amount is comprised between mg and 200 mg per day.
Another aspect of the invention is related to a process for the preparation of a pharmaceutical composition comprising a compound of the formula (I) or (I').
According to said process, one or more active ingredients of the formula (I) or (I') are mixing with inert excipients in a manner known per se.
Compounds of formula (I) and (I') or the above-mentioned pharmaceutical compositions are also of use in combination with other pharmacologically active compounds such as ACE-inhibitors, neutral endopeptidase inhibitors, angiotensin II receptor antagonists, endothelin receptors antagonists, vasodilators, calcium antagonists, potassium activators, diuretics, sympatholitics, beta-adrenergic antagonists, alpha-adrenergic antagonists, and/or other drugs beneficial for the prevention or the treatment of the above-mentioned diseases such as aldosterone antagonists, 1lbeta-hydroxysteroid dehydrogenase type 1 inhibitors and soluble guanylate cyclase activators.
The present invention also relates to pro-drugs of a compound of formula (I) or (I') that convert in vivo to the compound of formula (I) or (I') as such. Any reference to a compound of formula (I) or (I') is therefore to be understood as referring also to the corresponding pro-drugs of the compound of formula (I) or (I'), as appropriate and expedient.
The compounds of the formula (I) and (I') can be manufactured by the methods outlined below, by the method described in the example or by analogous methods.
Preparation of the compounds of formula (I ) and (ID:
The synthesis of the compounds of formula (I) and (I') described hereby is one possible synthesis among many other alternatives. Other synthetic routes and methodologies will be apparent to the skilled person in the art.
In a more particularly preferred embodiment, this amount is comprised between mg and 200 mg per day.
Another aspect of the invention is related to a process for the preparation of a pharmaceutical composition comprising a compound of the formula (I) or (I').
According to said process, one or more active ingredients of the formula (I) or (I') are mixing with inert excipients in a manner known per se.
Compounds of formula (I) and (I') or the above-mentioned pharmaceutical compositions are also of use in combination with other pharmacologically active compounds such as ACE-inhibitors, neutral endopeptidase inhibitors, angiotensin II receptor antagonists, endothelin receptors antagonists, vasodilators, calcium antagonists, potassium activators, diuretics, sympatholitics, beta-adrenergic antagonists, alpha-adrenergic antagonists, and/or other drugs beneficial for the prevention or the treatment of the above-mentioned diseases such as aldosterone antagonists, 1lbeta-hydroxysteroid dehydrogenase type 1 inhibitors and soluble guanylate cyclase activators.
The present invention also relates to pro-drugs of a compound of formula (I) or (I') that convert in vivo to the compound of formula (I) or (I') as such. Any reference to a compound of formula (I) or (I') is therefore to be understood as referring also to the corresponding pro-drugs of the compound of formula (I) or (I'), as appropriate and expedient.
The compounds of the formula (I) and (I') can be manufactured by the methods outlined below, by the method described in the example or by analogous methods.
Preparation of the compounds of formula (I ) and (ID:
The synthesis of the compounds of formula (I) and (I') described hereby is one possible synthesis among many other alternatives. Other synthetic routes and methodologies will be apparent to the skilled person in the art.
The bicyclononane derivative 3 (Scheme 1) can be prepared as racemate as described earlier (WO 2003/093267). Preparation of the vinylic triflate 6 proceeds using sodium hydride and N-phenyl-bis(trifluoromethanesulfonimide).
A Negishi-coupling between the bicyclic system 6 and the bromophenyl derivative leads to diazabicyclonene 7. Bromophenyl derivative 10 is prepared in three steps from 1,4-dibromobenzene, via a Grignard reaction with allyl bromide (->
compound 8), then a hydroboration (-> compound 9) and finally protection of the hydroxy substituent as a silyl ether. Bicyclononene 7 is then transprotected to 10 bicyclononene 11. A Mitsunobu-type coupling with 2-chloro-3,6-difluorophenol leads to derivative 12. Saponification of the ethyl ester under strongly basic conditions leads to a mixture of carboxylic acid derivatives 13 and 14.
A Negishi-coupling between the bicyclic system 6 and the bromophenyl derivative leads to diazabicyclonene 7. Bromophenyl derivative 10 is prepared in three steps from 1,4-dibromobenzene, via a Grignard reaction with allyl bromide (->
compound 8), then a hydroboration (-> compound 9) and finally protection of the hydroxy substituent as a silyl ether. Bicyclononene 7 is then transprotected to 10 bicyclononene 11. A Mitsunobu-type coupling with 2-chloro-3,6-difluorophenol leads to derivative 12. Saponification of the ethyl ester under strongly basic conditions leads to a mixture of carboxylic acid derivatives 13 and 14.
Scheme 1 Br Mg, allyl bromide, Et20, 61 %
Br Br Boc Boc 8 N NaH, Tf2NPh, N
THF, rt, 92% I
EtO N Et0 N 6 BH3, NaOH, \ H202, THF, 0 0 0 OTf H2O, 44%
3 Br Br BuLi, Imidazole, 9 ZnCl2, TBDMS-CI, Pd(PPh3)4 DMF, 90%
THF, 95%
OTBDMS OH
Boc N Boc 7 1) CICOOCHCICH3, N
N NaHCO3, CH2CICH2CI Bo EtO 2) MeOH EtO N 11 O 3) Boc20, DIPEA, O
CH2C12, 86%
~ \ F\
Boc Boc Boc F CI
I N OTBDMS N OH
N OH
Bo Bo Bo Azadicarboxylic HO j N N dipiperidide, HO Et0 PBu3, toluene, O O NaOH, H2O, EtOH, O 94%
I I 95%
\ + \ \ 12 O O O
CI / F CI , F CI / F
F\ ~ F\ ~ F\ ~
The mixture of compounds 13 and 14 is not separated and used directly further in the amide coupling step with amine derivative 16, which is prepared in one step using a reductive amination (Scheme 2). Amide coupling product 15 is obtained.
Cleavage of both Boc-protecting groups leads to a compound of formula (I).
Scheme 2 Boc Boc N
N ~
Bo Bo i i N
HO HO %
O O
+
O O
ci / F
/ F CI F~ I
F \ I
Cyclopropylamine, CI
EDC HCI, NaBH4, MeOH, HOBt, 7 87% CI
DMAP, -O
DIPEA, ci I NH
CH2CI2, ci 16 50%
Boc N H
/ Bo N
~ N
ci \ N N N
ci O CI
/ I
ci O
~ ~~) \ I
O
ci / F O
\ I CI / F
F
F
Enantioselective synthesis:
The compounds of the present invention contain two chiral centers which, however, are not independent from each other. The synthetic method presented so far leads to a racemate. The racemate can be separated into the compound of formula (I') and its enantiomer using a chiral HPLC-column. Also, both enantiomers might be prepared selectively starting from a meso-bicyclononane derivative, like compound 17 (Scheme 3), using an enantioselective acylation (Majewski M., Lasny R., J. Org. Chem., 1995, 60, 5825), as described in WO
2003/093267. Another alternative would be a resolution of the racemate using a chiral, organic acid derivative.
Scheme 3 O Rb02C O
-N Boc Boc N N
17 Rb = methyl, benzyl The following examples serve to illustrate the present invention in more detail. It is, however, not intended to limit its scope in any manner.
2o Examples General remarks The compound is characterized at least by LC-MS and 1H-NMR. Only the LC-MS data are given here.
HPLC- or LC-MS-conditions (if not indicated otherwise):
Analytic: Zorbax 59 SB Aqua column, 4.6 x 50 mm from Agilent Technologies.
Eluents: A: Acetonitrile; B: H20 + 0.5% TFA. Gradient: 90% B-> 5% B over 2 min. Flow: 1 mL/min. Detection: UV/Vis + MS.
Preparative: Zorbax SB Aqua column, 20 x 500 mm from Agilent Technologies.
Eluent: A: Acetonitrile; B: H20 + 0.05% ammonium hydroxide (25% aq.).
Gradient: 80% B-> 10% B over 6 min. Flow: 40 mL/min. Detection: UV + MS, or UV + ELSD.
Chiral, analytic: Regis Whelk column, 4.6 x 250 mm, 10 m. Eluent A: EtOH +
0.05% Et3N. Eluent B: hexane. Isocratic conditions, 60% B, over 40 min, 1 mL/min. The isocratic mixture may vary, depending on the compounds.
Chiral, preparative: As analytical conditions, but on a Regis Whelk 01 column, 50x250 mm and a flow of 100 mL/min.
All tR are given in min.
Abbreviations (as used herein) ACE Angiotensin Converting Enzyme Ang Angiotensin aq. aqueous Boc tert-Butyloxycarbonyl BSA Bovine serum albumine Bu butyl BuLi n-Butyllithium DIPEA Diisopropylethylamine DMAP 4-N,N-Dimethylaminopyridine DMF N,N-dimethylformamide DMSO Dimethylsulfoxide EDC=HC1 Ethyl-N,N-dimethylaminopropylcarbodiimide hydrochloride EIA Enzyme immunoassay ELSD Evaporative Light-Scattering Detection ES+ Electrospray, positive ionization Et Ethyl EtOAc Ethyl acetate EtOH Ethanol FC Flash Chromatography h hour(s) HOBt Hydroxybenzotriazol HPLC high performance liquid chromatography LC-MS Liquid chromatography - mass spectrometry MeOH Methanol min minute(s) MS mass spectrometry org. organic Ph Phenyl rt room temperature sat. saturated sol. Solution TBDMS tert-Butyldimethylsilyl Tf Trifluoromethylsulfonyl TFA trifluoroacetic acid THF Tetrahydrofuran tR retention time UV ultra violet vis visible Compound 6 Compound 3 (WO 2003/093267, 99.58 g, 305 mmol) was dissolved in dry THF
(1450 mL) under a nitrogene atmosphere and the mixture was cooled to 0 C.
NaH (16.64 g; 55 % dispersion in mineral oil, 381 mmol) was added by portions of 2 g over a period of 35 min, keeping the temperature between 0 and 4 C. H2 gas evolved. After the addition the mixture was yellow-green and was a slight suspension. The reaction mixture was stirred for 75 min at 0 to 4 C. Tf2NPh (128.6g, 360 mmol) was then added as a solid within 5 min. The reaction mixture became brown. The cooling bath was removed and the reaction was stirred over the weekend at rt. The reaction mixture was poured onto 1 L of ice/water and the THF was removed under reduced pressure. The remaining water phase was extracted with (3 x 500mL) EtOAc. The combined organic layers were washed with water (500 mL) and brine (500 mL). The organic phase was then dried over MgSO4, filtered, and evaporated under reduced pressure. To the crude brown residue (174 g) was added 50 mL of pentane and the mixture was stirred at 4 C
overnight. The crystals were filtered off and washed with cold hexane (70mL) and a cold mixture of hexane/diethylether (4:1, 100 mL). This resulted in 84 g of product containing some TfNHPh. This material was filtered over silicagel (75 g).
TfNHPh was washed out with CH2C12. This product was subsequently washed out with EtOAc (3 times 1 L) to give the title compound after evaporation under reduced pressure. The title compound was obtained in three fractions: a) 44.45 g of off-white crystals, b) 27.98 g of little brown crystals, and c) 15 g of a yellow oil containing the product and TfNHPh. After 2 days the TfNHPh contained in fractions c) had crystallised. It was filtered to yield 9.43 g of the product as a brown oil.
Treatment of the mother liquors:
The combined mother liquors obtained above were concentrated under vacuo. The brown oil residue (75 g) was purified by FC (1500 g silica gel) using a gradient of (EtOAc/heptane 1:9 -> EtOAc). The column was then washed with EtOAc/MeOH 9:1. The title compound was isolated as 25.44 g of an off-white solid as the pure product. LC-MS: tR = 0.87 min; ES+: 459.24.
Compound 7 A sol. of compound 10 (102.1 g, 310 mmol) in THF (1.50 L) under nitrogen was cooled to -78 C. BuLi (1.5M in hexane, 212 mL, 318 mmol) was added. After min, ZnC12 (1M in THF, 465 mL, 465 mmol) was added. The mixture was 25 allowed to warm up to rt. Compound 6 (83.6 g, 155 mmol) in THF (100 mL) and then Pd(PPh3)4 (4.48 g, 3.87 mmol) were added. The mixture was heated to reflux for 30 min, and allowed to cool to rt. The mixture was diluted with EtOAc and washed with aq. 1 M NaOH (lx). The org. extracts were dried over MgSO4, filtered and the solvents were removed under reduced pressure. Purification of the 30 residue by FC (MeOH/CH2C12 1:49 -> 1:24 -> 3:47 -> 2:23) yielded the title product (88.6 g, virtually quantitative). LC-MS: tR = 0.98 min; ES+: 559.24.
Compound 8 Mg (8.76 g, 360 mmol) was suspended in THF (90 mL) under nitrogen in a three-necked flask equipped with a condenser and a dropping funnel. The dropping funnel was filled with 1,4-dibromobenzene (77.3 g, 327 mmol) in THF (40 mL).
5 About 5% of the 1,4-dibromobenzene-sol. was added carefully to the Mg-suspension and the reaction was started with the help of a heat gun. When the reaction started, the 1,4-dibromobenzene-sol. was added to such a speed so that the reaction mixture was refluxing gently (about 20 min). The mixture was stirred for further 30 min, and was cooled to 0 C. THF (100 mL) was added and the 10 dropping funnel was filled with a sol. of allyl bromide (30.5 mL, 360 mmol) in THF (50 mL). The allyl bromide sol. was added slowly, maintaining the reaction temperature below 20 C. When the addition was complete, the mixture was stirred for further 30 min, while cooling to 0 C. Aq. 1M HC1 was added. The mixture was diluted with Et20, and washed with aq. 1 M HC1 and brine. The 15 combined aq. extracts were extracted back with Et20. The combined org.
extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Distillation of the residue (11 mbar, 88-92 C) yielded the title compound (39.3 g, about 61 %), together with another, unidentified impurity.
Compound 9 BH3 (1 M in THF, 412 mL, 412 mmol) was added to a sol. of compound 8 (204 g, 1.03 mmol) in THF (1.00 L) under nitrogen at 0 C. The mixture was stirred overnight while warming up to rt. Aq. NaOH (2.5M, 1.65 L, 4.12 mol) was added, and the mixture was cooled to 0 C. H202 (35%, 480 mL, 5.15 mol) was dropped carefully, and the mixture was stirred for 3 h. Et20 was added, and the phases were separated. The org. layer was washed with water (lx), and brine (lx). The org. layer was dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Purification by FC (Et20/petroleum ether 1:1 ~
Et20) yielded the title compound (97.4 g, 44%).
Compound 10 A sol. of compound 9 (49.4 g, 230 mmol) in DMF (500 mL) was cooled to 0 C, and imidazole (23.77 g, 349 mmol) and TBDMS-Cl (52.6 g, 349 mmol) were added. The mixture was stirred overnight, while warming up to rt. The mixture was diluted with heptane (1.0 L) and aq. sat. NH4C1 (800 mL), and the mixture was shaken. The layers were separated. The aq. layer was extracted with heptane, and the combined org. extracts were washed with brine. The org. extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Purification by FC (Et20/heptane 1:99 -> 1:19) yielded the title compound (68.1 g, 90%). LC-MS: tR = 1.24 min; ES+: not visible.
Compound 11 Compound 7 (32.0 g, 57.3 mmol) was dissolved in dry 1,2-dichlorethane (590 mL). NaHCO3 (48.2 g, 573 mmol) and 1-chloroethyl chloroformate (62.5 mL, 573 mmol) were added, and the suspension was heated to 80 C. After 3 h the reaction mixture was allowed to cool to rt. The mixture was filtered and the filtrate was evaporated under reduced pressure. The residue was dried 15 min under high vacuum. The product was then diluted in MeOH (400 mL), and the mixture was heated to 50 C for 20 min. The reaction mixture was allowed to cool to rt, and the solvents were removed under reduced pressure. The yellow solid was dried under high vacuum for 1 h. The solid was dissolved in CH2C12 (190 mL), and the solution was cooled to 0 C. DIPEA (49.1 mL, 287 mmol), and Boc2O (37.5 g, 172 mmol) were added. The reaction mixture was stirred overnight while warming up to rt. The reaction mixture was diluted with CH2C12 (110 mL). The organic layer was washed with aq. 1M HC1 (2 x 300mL), and aq. sat. NaHCO3 (300mL). The org. layer was dried over MgSO4, filtered, and the solvents were evaporated under reduced pressure. Purification of the residue by FC
(CH2C12/MeOH 100:0 -> 2:98 -> 5:95) yielded the title compound (26.2 g, 86%).
LC-MS: tR = 1.05 min; ES+: 531.33.
Compound 12 A mixture of compound 11 (56.0 g, 106 mmol), 2-chloro-3,6-difluorophenol (34.8 g, 211 mmol), azadicarboxylic dipiperidide (53.4 g, 211 mmol) and PBu3 (85%, 83 mL, 317 mmol) in toluene (1.20 L) was heated to reflux under nitrogen for 1 h.
The mixture was allowed to cool to rt. The mixture was diluted with EtOAc (2.00 L), and the mixture was washed with aq. 1M NaOH (2 x 900 mL). The org.
extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC (EtOAc/heptane 1:19 ->
1:1) yielded the title compound (67.5 g, 94%). LC-MS: tR = 1.24 min; ES+: 617.25.
Compounds 13 and 14 A mixture of compound 12 (67.5 g, 99.6 mmol) in aq. 1M NaOH (700 mL) and EtOH (1.40 L) was stirred at 80 C overnight. The mixture was partially evaporated under reduced pressure, and EtOAc (500 mL) was added. The aq.
phase was acidified with aq. 3M HCI, and the mixture was extracted. The org.
layer was separated, dried over MgSO4, filtered, and the solvents were removed under reduced pressure. The residue was dried under high vacuum, giving a 1:1 mixture of compounds 13 and 14, which was used further without purification (61.8 g, 95%). LC-MS: tR =1.12 and 1.14 min; ES+: 649.37.
Compound 15 A mixture of compounds 13 and 14 (20.7 g, 32.0 mmol), compound 16 (17.3 g, 80 mmol), EDC=HC1 (18.4 g, 96 mmol), HOBt (5.40 g, 40.0 mmol), DMAP (0.98 g, 8.00 mmol) and DIPEA (22.0 mL, 128 mmol) in CH2C12 (540 mL) was stirred at rt. The reaction was checked each day by LC-MS, and EDC=HC1 (6.13 g, 32 mmol) and DIPEA (5.5 mL, 32 mmol) were added if the reaction was not complete. When the reaction was complete, the mixture was diluted with more CH2C12, and was washed with aq. 1M HC1 (3x), and aq. sat. NaHCO3 (2x). The org. layer was dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Purification by FC yielded the title compound (16.5 g, 60%).
LC-MS: tR = 1.29 min; ES+: 848.35.
Compound 16 A mixture of 2,3-dichlorobenzaldehyde (90.0 g, 514 mmol) and cyclopropylamine (72 mL, 1.02 mol) in dry MeOH (1300 mL) was stirred at rt overnight. The reaction mixture was cooled to 0 C, and NaBH4 (25.3 g, 668 mmol) was added.
The reaction mixture was stirred again at rt overnight. Ice was added to the reaction mixture, and the solvents were evaporated under reduced pressure. The residue was dissolved in EtOAc, and was washed with aq. 1M NaOH. The aq.
layer was extracted with EtOAc (3x). The combined org. extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure.
Purification of the residue by FC (EtOAc / heptane 9:1 -> 1:1) yielded the title compound (97.4 g, 87%). LC-MS: tR = 0.64 min; ES+: 216.15.
Compound (I): (rac.)-(IR*, 5S*)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)-propyl]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclo-pr op yl-(2,3-dichlor ob enzyl)amide A sol. of compound 15 (16.5 g, 19.4 mmol) in CH2C12 (100 mL) was cooled to 0 C. HC1(4M in dioxane, 100 mL) was added. The mixture was stirred for 1 h at 0 C, then 1 h at rt. The solvents were removed under reduced pressure, and the residue was dried under high vacuum. The residue was diluted with CH2C12, and washed with aq. 1 M NaOH until the aq. layer staid basic. The org. extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC (MeOH/CH2C12 5:95 -> 10:90 ->
20:80) yielded the title compound (12.0 g, 95%). LC-MS: tR = 0.88 min; ES+:
648.36.
Compound (I'): (IR, 5S)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]-phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide Compound (I) (1.00 g, 1.55 mmol) was purified on a Regis Whelk 01 column, 50x250 mm using isocratic conditions (25% EtOH, 0.1% diethylamine, 75%
hexane) and a flow of 100 mL/min. The desired compound came as first enantiomer (tR = 20.00 min). After evaporating the solvents under reduced pressure, the residue was dried under high vacuum. The residue was dissolved in CH2C12, and washed with aq. 10% K2C03. The org. extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Drying the residue under high vacuum yielded the title compound (350 mg).
Biological Assays 1. Enzyme immuno assay (EIA) to estimate Ang I accumulation and renin inhibition 1.1 Preparation of Ang I-BSA conjugate 1.3 mg (1 mol) of Ang I[1-10 (Bachem, H-1680)] and 17 mg (0.26 mol) of BSA (Fluka, 05475) were dissolved in 4 mL of O.IM phosphate buffer, pH 7.4, after which 2 mL of a 1:100 dilution of glutaraldehyde in H20 (Sigma G-5882) was added dropwise. The mixture was incubated overnight at 4 C, then dialyzed against 2 liters of 0.9% NaC1, twice for 4 h at rt, followed by dialysis against 2 liters of PBS IX overnight at rt. The solution was then filtered with a Syringe filter, 0.45 m (Nalgene, Cat. No. 194-2545). The conjugate can be stored in polypropylene tubes in 0.05% sodium azide at 4 C for at least 12 months.
1.2 Preparation of BSA-Ang I coated MTP
Microtiter plates (MPT384, MaxiSorpTM, Nunc) were incubated overnight at 4 C with 80 l of Ang I (1-10)/BSA conjugate, diluted 1:100'000 in PBS IX in a teflon beaker (exact dilution dependent on batch of conjugate), emptied, filled with 90 l of blocking solution [0.5% BSA (Sigma A-2153) in PBS IX, 0.02%
NaN3], and incubated for at least 2 h at rt, or overnight at 4 C. 96 well MTP
(MaxiSorpTm, Nunc) were coated with 200 l conjugate and blocked with 250 l blocking solution as above, except that the blocking solution contained 3%
BSA.
The plates can be stored in blocking solution at 4 C for 1 month.
1.3 Ang I-EIA in 384 well MTP
The Ang I (1-10)/BSA coated MTP were washed 3 times with wash buffer (PBS
1 X, 0.01 % Tween 20) and filled with 75 l of primary antibody solution (anti-Ang I antiserum, pre-diluted 1:10 in horse serum), diluted to a final concentration of 1:100'000 in assay buffer (PBS IX, ImM EDTA, 0.1% BSA, pH 7.4). 5 l of the renin reaction (or standards in assay buffer) (see below) were added to the primary antibody solution and the plates were incubated overnight at 4 C.
After the incubation the plates were washed 3 times with wash buffer and incubated with secondary antibody [anti-rabbit IgG, linked to horseradish peroxidase 5 (Amersham Bioscience, NA 934V), diluted 1:2'000 in wash buffer] for 2 h at rt.
The plates were washed 3 times with wash buffer and then incubated for 1 h at rt with substrate solution [1.89mM ABTS (2.2'-azino-di-(3 -ethyl-benzthiazolinsulfonate)] (Roche Diagnostics, 102 946) and 2.36mM H202 [30%, (Fluka, 95300] in substrate buffer (0.1M sodium acetate, 0.05M sodium 10 dihydrogen phosphate, pH 4.2). The OD of the plate was read at 405 nm in a microplate reader (FLUOStar Optima from BMG). The production of Ang I
during the renin reaction was quantified by comparing the OD of the sample with the OD of a standard curve of Ang I(1-10), measured in parallel.
15 2. Primary renin inhibition assay: IC50 in buffer, 384 well MTP
The renin assay was adapted from an assay described before (Fischli W. et al., Hypertension, 1991, 18:22-31) and consists of two steps: in the first step, recombinant human renin is incubated with its substrate (commercial human tetradecapeptide renin substrate) to create the product Angiotensin I (Ang I).
In 20 the second step, the accumulated Ang I is measured by an immunological assay (enzyme immuno assay, EIA). The detailed description of this assay is found below. The EIA is very sensitive and well suited for renin activity measurements in buffer or in plasma. Due to the low concentration of renin used in this assay (2 fmol per assay tube or 10 pM) it is possible to measure inhibitor affinities in this primary assay down to low pM concentration.
2.1 Methodology Recombinant human renin (3 pg/ l) in assay buffer (PBS 1X, 1 mM EDTA, 0.1%
BSA, pH 7.4), human tetradecapeptide (1-14) substrate (Bachem, M-1120) [5 M
in 10 mM HCl], hydroxyquinoline sulfate (Fluka, 55100) [30 mM in H20] and assay buffer were premixed at 4 C at a ratio of 100:30:10:145. 47.5 l per well of this premix was transferred into polypropylene plates (MTP384, Nunc). Test compounds were dissolved and diluted in 100% DMSO and 2.5 l added to the premix, then incubated at 37 C for 3 h. At the end of the incubation period, 5 l of the renin reaction (or standards in assay buffer) were transferred into EIA
assays (as described above) and Ang I produced by renin was quantified. The percentage of renin inhibition (Ang I decrease) was calculated for each concentration of compound and the concentration of renin inhibition was determined that inhibited the enzyme activity by 50% (IC50). The IC50-values of all compounds tested are below 100 nM. However, selected compounds exhibit a very good bioavailability and are metabolically more stable than prior art compounds.
The compound of formula (I') displays an IC50-value of 0.5 nM.
Hemodynamic measurements (telemetry method) Animals - Female double transgenic rats with human renin and human angiotensinogen were purchased from RCC Ltd, Fullingsdorf, Switzerland. All animals were maintained under identical conditions and had free access to normal pelleted rat chow and water. Rats were initially treated with enalapril (1 mg/kg/day) during 2 months. After approximately two weeks following cessation of enalapril treatment the double transgenic rats become hypertensive and reach mean arterial blood pressures in the range of 160-170 mmHg.
Transmitter implantation - The rats were anaesthetised with a mixture of 90 mg/kg Ketamin-HC1 (Ketavet, Parke-Davis, Berlin FRG) and 10 mg/kg xylazin (Rompun, Bayer, Leverkusen, FRG) i.p. The pressure transmitter was implanted under aseptic conditions into the peritoneal cavity with the sensing catheter placed in the descending aorta below the renal arteries pointing upstream. The transmitter was sutured to the abdominal musculature and the skin closed.
Telemetry-System - Telemetry units were obtained from Data Sciences (St. Paul, MN). The implanted sensor consisted of a fluid-filled catheter (0.7 mm diameter, 8 cm long; model TA11PA-C40) connected to a highly stable low-conductance strain-gauge pressure transducer, which measured the absolute arterial pressure relative to a vacuum, and a radio-frequency transmitter. The tip of the catheter was filled with a viscous gel that prevents blood reflux and was coated with an antithrombogenic film to inhibit thrombus formation. The implants (length =
2.5 cm, diameter = 1.2 cm) weighted 9 g and have a typical battery life of 6 months. A
receiver platform (RPC-1, Data Sciences) connected the radio signal to digitized input that was sent to a dedicated personal computer (Compaq, deskpro).
Arterial pressures were calibrated by using an input from an ambient-pressure reference (APR-1, Data Sciences). Systolic, mean and diastolic blood pressure was expressed in millimeter of mercury (mmHg).
Hemodynamic measurements - Double transgenic rats with implanted pressure transmitters were dosed by oral gavage with vehicle or 10 mg/kg of the test substance (n=6 per group) and the mean arterial blood pressure was continuously monitored. The effect of the test substance is expressed as maximal decrease of mean arterial pressure (MAP) in the treated group versus the control group.
The compound of formula (I') is active in this animal model. It leeds to a blood pressure decrease of 26 mmHg at a single oral dose of 10 mg/kg, and a blood pressure decrease of 13 mmHg at a single oral dose of 3 mg/kg.
Br Br Boc Boc 8 N NaH, Tf2NPh, N
THF, rt, 92% I
EtO N Et0 N 6 BH3, NaOH, \ H202, THF, 0 0 0 OTf H2O, 44%
3 Br Br BuLi, Imidazole, 9 ZnCl2, TBDMS-CI, Pd(PPh3)4 DMF, 90%
THF, 95%
OTBDMS OH
Boc N Boc 7 1) CICOOCHCICH3, N
N NaHCO3, CH2CICH2CI Bo EtO 2) MeOH EtO N 11 O 3) Boc20, DIPEA, O
CH2C12, 86%
~ \ F\
Boc Boc Boc F CI
I N OTBDMS N OH
N OH
Bo Bo Bo Azadicarboxylic HO j N N dipiperidide, HO Et0 PBu3, toluene, O O NaOH, H2O, EtOH, O 94%
I I 95%
\ + \ \ 12 O O O
CI / F CI , F CI / F
F\ ~ F\ ~ F\ ~
The mixture of compounds 13 and 14 is not separated and used directly further in the amide coupling step with amine derivative 16, which is prepared in one step using a reductive amination (Scheme 2). Amide coupling product 15 is obtained.
Cleavage of both Boc-protecting groups leads to a compound of formula (I).
Scheme 2 Boc Boc N
N ~
Bo Bo i i N
HO HO %
O O
+
O O
ci / F
/ F CI F~ I
F \ I
Cyclopropylamine, CI
EDC HCI, NaBH4, MeOH, HOBt, 7 87% CI
DMAP, -O
DIPEA, ci I NH
CH2CI2, ci 16 50%
Boc N H
/ Bo N
~ N
ci \ N N N
ci O CI
/ I
ci O
~ ~~) \ I
O
ci / F O
\ I CI / F
F
F
Enantioselective synthesis:
The compounds of the present invention contain two chiral centers which, however, are not independent from each other. The synthetic method presented so far leads to a racemate. The racemate can be separated into the compound of formula (I') and its enantiomer using a chiral HPLC-column. Also, both enantiomers might be prepared selectively starting from a meso-bicyclononane derivative, like compound 17 (Scheme 3), using an enantioselective acylation (Majewski M., Lasny R., J. Org. Chem., 1995, 60, 5825), as described in WO
2003/093267. Another alternative would be a resolution of the racemate using a chiral, organic acid derivative.
Scheme 3 O Rb02C O
-N Boc Boc N N
17 Rb = methyl, benzyl The following examples serve to illustrate the present invention in more detail. It is, however, not intended to limit its scope in any manner.
2o Examples General remarks The compound is characterized at least by LC-MS and 1H-NMR. Only the LC-MS data are given here.
HPLC- or LC-MS-conditions (if not indicated otherwise):
Analytic: Zorbax 59 SB Aqua column, 4.6 x 50 mm from Agilent Technologies.
Eluents: A: Acetonitrile; B: H20 + 0.5% TFA. Gradient: 90% B-> 5% B over 2 min. Flow: 1 mL/min. Detection: UV/Vis + MS.
Preparative: Zorbax SB Aqua column, 20 x 500 mm from Agilent Technologies.
Eluent: A: Acetonitrile; B: H20 + 0.05% ammonium hydroxide (25% aq.).
Gradient: 80% B-> 10% B over 6 min. Flow: 40 mL/min. Detection: UV + MS, or UV + ELSD.
Chiral, analytic: Regis Whelk column, 4.6 x 250 mm, 10 m. Eluent A: EtOH +
0.05% Et3N. Eluent B: hexane. Isocratic conditions, 60% B, over 40 min, 1 mL/min. The isocratic mixture may vary, depending on the compounds.
Chiral, preparative: As analytical conditions, but on a Regis Whelk 01 column, 50x250 mm and a flow of 100 mL/min.
All tR are given in min.
Abbreviations (as used herein) ACE Angiotensin Converting Enzyme Ang Angiotensin aq. aqueous Boc tert-Butyloxycarbonyl BSA Bovine serum albumine Bu butyl BuLi n-Butyllithium DIPEA Diisopropylethylamine DMAP 4-N,N-Dimethylaminopyridine DMF N,N-dimethylformamide DMSO Dimethylsulfoxide EDC=HC1 Ethyl-N,N-dimethylaminopropylcarbodiimide hydrochloride EIA Enzyme immunoassay ELSD Evaporative Light-Scattering Detection ES+ Electrospray, positive ionization Et Ethyl EtOAc Ethyl acetate EtOH Ethanol FC Flash Chromatography h hour(s) HOBt Hydroxybenzotriazol HPLC high performance liquid chromatography LC-MS Liquid chromatography - mass spectrometry MeOH Methanol min minute(s) MS mass spectrometry org. organic Ph Phenyl rt room temperature sat. saturated sol. Solution TBDMS tert-Butyldimethylsilyl Tf Trifluoromethylsulfonyl TFA trifluoroacetic acid THF Tetrahydrofuran tR retention time UV ultra violet vis visible Compound 6 Compound 3 (WO 2003/093267, 99.58 g, 305 mmol) was dissolved in dry THF
(1450 mL) under a nitrogene atmosphere and the mixture was cooled to 0 C.
NaH (16.64 g; 55 % dispersion in mineral oil, 381 mmol) was added by portions of 2 g over a period of 35 min, keeping the temperature between 0 and 4 C. H2 gas evolved. After the addition the mixture was yellow-green and was a slight suspension. The reaction mixture was stirred for 75 min at 0 to 4 C. Tf2NPh (128.6g, 360 mmol) was then added as a solid within 5 min. The reaction mixture became brown. The cooling bath was removed and the reaction was stirred over the weekend at rt. The reaction mixture was poured onto 1 L of ice/water and the THF was removed under reduced pressure. The remaining water phase was extracted with (3 x 500mL) EtOAc. The combined organic layers were washed with water (500 mL) and brine (500 mL). The organic phase was then dried over MgSO4, filtered, and evaporated under reduced pressure. To the crude brown residue (174 g) was added 50 mL of pentane and the mixture was stirred at 4 C
overnight. The crystals were filtered off and washed with cold hexane (70mL) and a cold mixture of hexane/diethylether (4:1, 100 mL). This resulted in 84 g of product containing some TfNHPh. This material was filtered over silicagel (75 g).
TfNHPh was washed out with CH2C12. This product was subsequently washed out with EtOAc (3 times 1 L) to give the title compound after evaporation under reduced pressure. The title compound was obtained in three fractions: a) 44.45 g of off-white crystals, b) 27.98 g of little brown crystals, and c) 15 g of a yellow oil containing the product and TfNHPh. After 2 days the TfNHPh contained in fractions c) had crystallised. It was filtered to yield 9.43 g of the product as a brown oil.
Treatment of the mother liquors:
The combined mother liquors obtained above were concentrated under vacuo. The brown oil residue (75 g) was purified by FC (1500 g silica gel) using a gradient of (EtOAc/heptane 1:9 -> EtOAc). The column was then washed with EtOAc/MeOH 9:1. The title compound was isolated as 25.44 g of an off-white solid as the pure product. LC-MS: tR = 0.87 min; ES+: 459.24.
Compound 7 A sol. of compound 10 (102.1 g, 310 mmol) in THF (1.50 L) under nitrogen was cooled to -78 C. BuLi (1.5M in hexane, 212 mL, 318 mmol) was added. After min, ZnC12 (1M in THF, 465 mL, 465 mmol) was added. The mixture was 25 allowed to warm up to rt. Compound 6 (83.6 g, 155 mmol) in THF (100 mL) and then Pd(PPh3)4 (4.48 g, 3.87 mmol) were added. The mixture was heated to reflux for 30 min, and allowed to cool to rt. The mixture was diluted with EtOAc and washed with aq. 1 M NaOH (lx). The org. extracts were dried over MgSO4, filtered and the solvents were removed under reduced pressure. Purification of the 30 residue by FC (MeOH/CH2C12 1:49 -> 1:24 -> 3:47 -> 2:23) yielded the title product (88.6 g, virtually quantitative). LC-MS: tR = 0.98 min; ES+: 559.24.
Compound 8 Mg (8.76 g, 360 mmol) was suspended in THF (90 mL) under nitrogen in a three-necked flask equipped with a condenser and a dropping funnel. The dropping funnel was filled with 1,4-dibromobenzene (77.3 g, 327 mmol) in THF (40 mL).
5 About 5% of the 1,4-dibromobenzene-sol. was added carefully to the Mg-suspension and the reaction was started with the help of a heat gun. When the reaction started, the 1,4-dibromobenzene-sol. was added to such a speed so that the reaction mixture was refluxing gently (about 20 min). The mixture was stirred for further 30 min, and was cooled to 0 C. THF (100 mL) was added and the 10 dropping funnel was filled with a sol. of allyl bromide (30.5 mL, 360 mmol) in THF (50 mL). The allyl bromide sol. was added slowly, maintaining the reaction temperature below 20 C. When the addition was complete, the mixture was stirred for further 30 min, while cooling to 0 C. Aq. 1M HC1 was added. The mixture was diluted with Et20, and washed with aq. 1 M HC1 and brine. The 15 combined aq. extracts were extracted back with Et20. The combined org.
extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Distillation of the residue (11 mbar, 88-92 C) yielded the title compound (39.3 g, about 61 %), together with another, unidentified impurity.
Compound 9 BH3 (1 M in THF, 412 mL, 412 mmol) was added to a sol. of compound 8 (204 g, 1.03 mmol) in THF (1.00 L) under nitrogen at 0 C. The mixture was stirred overnight while warming up to rt. Aq. NaOH (2.5M, 1.65 L, 4.12 mol) was added, and the mixture was cooled to 0 C. H202 (35%, 480 mL, 5.15 mol) was dropped carefully, and the mixture was stirred for 3 h. Et20 was added, and the phases were separated. The org. layer was washed with water (lx), and brine (lx). The org. layer was dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Purification by FC (Et20/petroleum ether 1:1 ~
Et20) yielded the title compound (97.4 g, 44%).
Compound 10 A sol. of compound 9 (49.4 g, 230 mmol) in DMF (500 mL) was cooled to 0 C, and imidazole (23.77 g, 349 mmol) and TBDMS-Cl (52.6 g, 349 mmol) were added. The mixture was stirred overnight, while warming up to rt. The mixture was diluted with heptane (1.0 L) and aq. sat. NH4C1 (800 mL), and the mixture was shaken. The layers were separated. The aq. layer was extracted with heptane, and the combined org. extracts were washed with brine. The org. extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Purification by FC (Et20/heptane 1:99 -> 1:19) yielded the title compound (68.1 g, 90%). LC-MS: tR = 1.24 min; ES+: not visible.
Compound 11 Compound 7 (32.0 g, 57.3 mmol) was dissolved in dry 1,2-dichlorethane (590 mL). NaHCO3 (48.2 g, 573 mmol) and 1-chloroethyl chloroformate (62.5 mL, 573 mmol) were added, and the suspension was heated to 80 C. After 3 h the reaction mixture was allowed to cool to rt. The mixture was filtered and the filtrate was evaporated under reduced pressure. The residue was dried 15 min under high vacuum. The product was then diluted in MeOH (400 mL), and the mixture was heated to 50 C for 20 min. The reaction mixture was allowed to cool to rt, and the solvents were removed under reduced pressure. The yellow solid was dried under high vacuum for 1 h. The solid was dissolved in CH2C12 (190 mL), and the solution was cooled to 0 C. DIPEA (49.1 mL, 287 mmol), and Boc2O (37.5 g, 172 mmol) were added. The reaction mixture was stirred overnight while warming up to rt. The reaction mixture was diluted with CH2C12 (110 mL). The organic layer was washed with aq. 1M HC1 (2 x 300mL), and aq. sat. NaHCO3 (300mL). The org. layer was dried over MgSO4, filtered, and the solvents were evaporated under reduced pressure. Purification of the residue by FC
(CH2C12/MeOH 100:0 -> 2:98 -> 5:95) yielded the title compound (26.2 g, 86%).
LC-MS: tR = 1.05 min; ES+: 531.33.
Compound 12 A mixture of compound 11 (56.0 g, 106 mmol), 2-chloro-3,6-difluorophenol (34.8 g, 211 mmol), azadicarboxylic dipiperidide (53.4 g, 211 mmol) and PBu3 (85%, 83 mL, 317 mmol) in toluene (1.20 L) was heated to reflux under nitrogen for 1 h.
The mixture was allowed to cool to rt. The mixture was diluted with EtOAc (2.00 L), and the mixture was washed with aq. 1M NaOH (2 x 900 mL). The org.
extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC (EtOAc/heptane 1:19 ->
1:1) yielded the title compound (67.5 g, 94%). LC-MS: tR = 1.24 min; ES+: 617.25.
Compounds 13 and 14 A mixture of compound 12 (67.5 g, 99.6 mmol) in aq. 1M NaOH (700 mL) and EtOH (1.40 L) was stirred at 80 C overnight. The mixture was partially evaporated under reduced pressure, and EtOAc (500 mL) was added. The aq.
phase was acidified with aq. 3M HCI, and the mixture was extracted. The org.
layer was separated, dried over MgSO4, filtered, and the solvents were removed under reduced pressure. The residue was dried under high vacuum, giving a 1:1 mixture of compounds 13 and 14, which was used further without purification (61.8 g, 95%). LC-MS: tR =1.12 and 1.14 min; ES+: 649.37.
Compound 15 A mixture of compounds 13 and 14 (20.7 g, 32.0 mmol), compound 16 (17.3 g, 80 mmol), EDC=HC1 (18.4 g, 96 mmol), HOBt (5.40 g, 40.0 mmol), DMAP (0.98 g, 8.00 mmol) and DIPEA (22.0 mL, 128 mmol) in CH2C12 (540 mL) was stirred at rt. The reaction was checked each day by LC-MS, and EDC=HC1 (6.13 g, 32 mmol) and DIPEA (5.5 mL, 32 mmol) were added if the reaction was not complete. When the reaction was complete, the mixture was diluted with more CH2C12, and was washed with aq. 1M HC1 (3x), and aq. sat. NaHCO3 (2x). The org. layer was dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Purification by FC yielded the title compound (16.5 g, 60%).
LC-MS: tR = 1.29 min; ES+: 848.35.
Compound 16 A mixture of 2,3-dichlorobenzaldehyde (90.0 g, 514 mmol) and cyclopropylamine (72 mL, 1.02 mol) in dry MeOH (1300 mL) was stirred at rt overnight. The reaction mixture was cooled to 0 C, and NaBH4 (25.3 g, 668 mmol) was added.
The reaction mixture was stirred again at rt overnight. Ice was added to the reaction mixture, and the solvents were evaporated under reduced pressure. The residue was dissolved in EtOAc, and was washed with aq. 1M NaOH. The aq.
layer was extracted with EtOAc (3x). The combined org. extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure.
Purification of the residue by FC (EtOAc / heptane 9:1 -> 1:1) yielded the title compound (97.4 g, 87%). LC-MS: tR = 0.64 min; ES+: 216.15.
Compound (I): (rac.)-(IR*, 5S*)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)-propyl]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclo-pr op yl-(2,3-dichlor ob enzyl)amide A sol. of compound 15 (16.5 g, 19.4 mmol) in CH2C12 (100 mL) was cooled to 0 C. HC1(4M in dioxane, 100 mL) was added. The mixture was stirred for 1 h at 0 C, then 1 h at rt. The solvents were removed under reduced pressure, and the residue was dried under high vacuum. The residue was diluted with CH2C12, and washed with aq. 1 M NaOH until the aq. layer staid basic. The org. extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Purification of the residue by FC (MeOH/CH2C12 5:95 -> 10:90 ->
20:80) yielded the title compound (12.0 g, 95%). LC-MS: tR = 0.88 min; ES+:
648.36.
Compound (I'): (IR, 5S)-7-{4-[3-(2-Chloro-3,6-difluorophenoxy)propyl]-phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide Compound (I) (1.00 g, 1.55 mmol) was purified on a Regis Whelk 01 column, 50x250 mm using isocratic conditions (25% EtOH, 0.1% diethylamine, 75%
hexane) and a flow of 100 mL/min. The desired compound came as first enantiomer (tR = 20.00 min). After evaporating the solvents under reduced pressure, the residue was dried under high vacuum. The residue was dissolved in CH2C12, and washed with aq. 10% K2C03. The org. extracts were dried over MgSO4, filtered, and the solvents were removed under reduced pressure. Drying the residue under high vacuum yielded the title compound (350 mg).
Biological Assays 1. Enzyme immuno assay (EIA) to estimate Ang I accumulation and renin inhibition 1.1 Preparation of Ang I-BSA conjugate 1.3 mg (1 mol) of Ang I[1-10 (Bachem, H-1680)] and 17 mg (0.26 mol) of BSA (Fluka, 05475) were dissolved in 4 mL of O.IM phosphate buffer, pH 7.4, after which 2 mL of a 1:100 dilution of glutaraldehyde in H20 (Sigma G-5882) was added dropwise. The mixture was incubated overnight at 4 C, then dialyzed against 2 liters of 0.9% NaC1, twice for 4 h at rt, followed by dialysis against 2 liters of PBS IX overnight at rt. The solution was then filtered with a Syringe filter, 0.45 m (Nalgene, Cat. No. 194-2545). The conjugate can be stored in polypropylene tubes in 0.05% sodium azide at 4 C for at least 12 months.
1.2 Preparation of BSA-Ang I coated MTP
Microtiter plates (MPT384, MaxiSorpTM, Nunc) were incubated overnight at 4 C with 80 l of Ang I (1-10)/BSA conjugate, diluted 1:100'000 in PBS IX in a teflon beaker (exact dilution dependent on batch of conjugate), emptied, filled with 90 l of blocking solution [0.5% BSA (Sigma A-2153) in PBS IX, 0.02%
NaN3], and incubated for at least 2 h at rt, or overnight at 4 C. 96 well MTP
(MaxiSorpTm, Nunc) were coated with 200 l conjugate and blocked with 250 l blocking solution as above, except that the blocking solution contained 3%
BSA.
The plates can be stored in blocking solution at 4 C for 1 month.
1.3 Ang I-EIA in 384 well MTP
The Ang I (1-10)/BSA coated MTP were washed 3 times with wash buffer (PBS
1 X, 0.01 % Tween 20) and filled with 75 l of primary antibody solution (anti-Ang I antiserum, pre-diluted 1:10 in horse serum), diluted to a final concentration of 1:100'000 in assay buffer (PBS IX, ImM EDTA, 0.1% BSA, pH 7.4). 5 l of the renin reaction (or standards in assay buffer) (see below) were added to the primary antibody solution and the plates were incubated overnight at 4 C.
After the incubation the plates were washed 3 times with wash buffer and incubated with secondary antibody [anti-rabbit IgG, linked to horseradish peroxidase 5 (Amersham Bioscience, NA 934V), diluted 1:2'000 in wash buffer] for 2 h at rt.
The plates were washed 3 times with wash buffer and then incubated for 1 h at rt with substrate solution [1.89mM ABTS (2.2'-azino-di-(3 -ethyl-benzthiazolinsulfonate)] (Roche Diagnostics, 102 946) and 2.36mM H202 [30%, (Fluka, 95300] in substrate buffer (0.1M sodium acetate, 0.05M sodium 10 dihydrogen phosphate, pH 4.2). The OD of the plate was read at 405 nm in a microplate reader (FLUOStar Optima from BMG). The production of Ang I
during the renin reaction was quantified by comparing the OD of the sample with the OD of a standard curve of Ang I(1-10), measured in parallel.
15 2. Primary renin inhibition assay: IC50 in buffer, 384 well MTP
The renin assay was adapted from an assay described before (Fischli W. et al., Hypertension, 1991, 18:22-31) and consists of two steps: in the first step, recombinant human renin is incubated with its substrate (commercial human tetradecapeptide renin substrate) to create the product Angiotensin I (Ang I).
In 20 the second step, the accumulated Ang I is measured by an immunological assay (enzyme immuno assay, EIA). The detailed description of this assay is found below. The EIA is very sensitive and well suited for renin activity measurements in buffer or in plasma. Due to the low concentration of renin used in this assay (2 fmol per assay tube or 10 pM) it is possible to measure inhibitor affinities in this primary assay down to low pM concentration.
2.1 Methodology Recombinant human renin (3 pg/ l) in assay buffer (PBS 1X, 1 mM EDTA, 0.1%
BSA, pH 7.4), human tetradecapeptide (1-14) substrate (Bachem, M-1120) [5 M
in 10 mM HCl], hydroxyquinoline sulfate (Fluka, 55100) [30 mM in H20] and assay buffer were premixed at 4 C at a ratio of 100:30:10:145. 47.5 l per well of this premix was transferred into polypropylene plates (MTP384, Nunc). Test compounds were dissolved and diluted in 100% DMSO and 2.5 l added to the premix, then incubated at 37 C for 3 h. At the end of the incubation period, 5 l of the renin reaction (or standards in assay buffer) were transferred into EIA
assays (as described above) and Ang I produced by renin was quantified. The percentage of renin inhibition (Ang I decrease) was calculated for each concentration of compound and the concentration of renin inhibition was determined that inhibited the enzyme activity by 50% (IC50). The IC50-values of all compounds tested are below 100 nM. However, selected compounds exhibit a very good bioavailability and are metabolically more stable than prior art compounds.
The compound of formula (I') displays an IC50-value of 0.5 nM.
Hemodynamic measurements (telemetry method) Animals - Female double transgenic rats with human renin and human angiotensinogen were purchased from RCC Ltd, Fullingsdorf, Switzerland. All animals were maintained under identical conditions and had free access to normal pelleted rat chow and water. Rats were initially treated with enalapril (1 mg/kg/day) during 2 months. After approximately two weeks following cessation of enalapril treatment the double transgenic rats become hypertensive and reach mean arterial blood pressures in the range of 160-170 mmHg.
Transmitter implantation - The rats were anaesthetised with a mixture of 90 mg/kg Ketamin-HC1 (Ketavet, Parke-Davis, Berlin FRG) and 10 mg/kg xylazin (Rompun, Bayer, Leverkusen, FRG) i.p. The pressure transmitter was implanted under aseptic conditions into the peritoneal cavity with the sensing catheter placed in the descending aorta below the renal arteries pointing upstream. The transmitter was sutured to the abdominal musculature and the skin closed.
Telemetry-System - Telemetry units were obtained from Data Sciences (St. Paul, MN). The implanted sensor consisted of a fluid-filled catheter (0.7 mm diameter, 8 cm long; model TA11PA-C40) connected to a highly stable low-conductance strain-gauge pressure transducer, which measured the absolute arterial pressure relative to a vacuum, and a radio-frequency transmitter. The tip of the catheter was filled with a viscous gel that prevents blood reflux and was coated with an antithrombogenic film to inhibit thrombus formation. The implants (length =
2.5 cm, diameter = 1.2 cm) weighted 9 g and have a typical battery life of 6 months. A
receiver platform (RPC-1, Data Sciences) connected the radio signal to digitized input that was sent to a dedicated personal computer (Compaq, deskpro).
Arterial pressures were calibrated by using an input from an ambient-pressure reference (APR-1, Data Sciences). Systolic, mean and diastolic blood pressure was expressed in millimeter of mercury (mmHg).
Hemodynamic measurements - Double transgenic rats with implanted pressure transmitters were dosed by oral gavage with vehicle or 10 mg/kg of the test substance (n=6 per group) and the mean arterial blood pressure was continuously monitored. The effect of the test substance is expressed as maximal decrease of mean arterial pressure (MAP) in the treated group versus the control group.
The compound of formula (I') is active in this animal model. It leeds to a blood pressure decrease of 26 mmHg at a single oral dose of 10 mg/kg, and a blood pressure decrease of 13 mmHg at a single oral dose of 3 mg/kg.
Claims (5)
1. A compound of formula (I) named as (IR*, 5S*)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide and optically pure enantiomers or a mixture of enantiomers such as a racemate;
as well as pharmaceutically acceptable salts, solvent complexes and morphological forms thereof.
as well as pharmaceutically acceptable salts, solvent complexes and morphological forms thereof.
2. Enantiomer of the compound of formula (I) according to claim 1 represented by formula (I') and named as (IR, 5S)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,9-diazabicyclo-[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide as well as pharmaceutically acceptable salts, solvent complexes and morphological forms thereof.
3. A pharmaceutical composition comprising a compound according to claim 1 or 2 and a pharmaceutically acceptable carrier material.
4. A compound according to claim 1 or 2, or composition according to claim 3, for use as a medicament.
5. Use of a compound according to claim 1 or 2 for the preparation of a pharmaceutical composition for the treatment and/or prophylaxis of diseases selected from hypertension, congestive heart failure, pulmonary hypertension, renal insufficiency, renal ischemia, renal failure, renal fibrosis, cardiac insufficiency, cardiac hypertrophy, cardiac fibrosis, myocardial ischemia, cardiomyopathy, glomerulonephritis, renal colic, complications resulting from diabetes such as nephropathy, vasculopathy and neuropathy, glaucoma, elevated intra-ocular pressure, atherosclerosis, restenosis post angioplasty, complications following vascular or cardiac surgery, erectile dysfunction, hyperaldosteronism, lung fibrosis, scleroderma, anxiety, cognitive disorders, complications of treatments with immunosuppressive agents, and other diseases known to be related to the renin-angiotensin system.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP2004/013949 | 2004-12-08 | ||
EP2004013949 | 2004-12-08 | ||
PCT/IB2005/054113 WO2006061791A2 (en) | 2004-12-08 | 2005-12-08 | Novel diazabicyclononene derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2589966A1 true CA2589966A1 (en) | 2006-06-15 |
Family
ID=36332872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002589966A Abandoned CA2589966A1 (en) | 2004-12-08 | 2005-12-08 | Novel diazabicyclononene derivative |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1824851A2 (en) |
JP (1) | JP2008522967A (en) |
KR (1) | KR20070086977A (en) |
CN (1) | CN101072776A (en) |
AR (1) | AR052263A1 (en) |
AU (1) | AU2005313002A1 (en) |
BR (1) | BRPI0518610A2 (en) |
CA (1) | CA2589966A1 (en) |
IL (1) | IL183754A0 (en) |
MX (1) | MX2007006745A (en) |
NO (1) | NO20073058L (en) |
RU (1) | RU2007125724A (en) |
TW (1) | TW200634014A (en) |
WO (1) | WO2006061791A2 (en) |
ZA (1) | ZA200705557B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE462703T1 (en) | 2004-08-25 | 2010-04-15 | Actelion Pharmaceuticals Ltd | BICYCLONONE DERIVATIVES AS RENIN INHIBITORS |
US8129538B1 (en) | 2007-03-28 | 2012-03-06 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
AU2008253519A1 (en) | 2007-05-24 | 2008-11-27 | Merck Frosst Canada Ltd | Novel case of renin inhibitors |
US8334308B2 (en) | 2007-08-20 | 2012-12-18 | Merck Sharp & Dohme Corp. | Renin inhibitors |
CA2722734C (en) | 2008-05-05 | 2013-11-05 | Merck Frosst Canada Ltd. | 3,4-substituted piperidine derivatives as renin inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003233963B2 (en) * | 2002-04-29 | 2008-09-11 | Actelion Pharmaceuticals Ltd | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases |
-
2005
- 2005-12-07 TW TW094143263A patent/TW200634014A/en unknown
- 2005-12-07 AR ARP050105127A patent/AR052263A1/en not_active Application Discontinuation
- 2005-12-08 WO PCT/IB2005/054113 patent/WO2006061791A2/en not_active Application Discontinuation
- 2005-12-08 AU AU2005313002A patent/AU2005313002A1/en not_active Abandoned
- 2005-12-08 EP EP05824541A patent/EP1824851A2/en not_active Withdrawn
- 2005-12-08 MX MX2007006745A patent/MX2007006745A/en not_active Application Discontinuation
- 2005-12-08 CN CNA2005800418079A patent/CN101072776A/en active Pending
- 2005-12-08 BR BRPI0518610-2A patent/BRPI0518610A2/en not_active Application Discontinuation
- 2005-12-08 JP JP2007543997A patent/JP2008522967A/en active Pending
- 2005-12-08 RU RU2007125724/04A patent/RU2007125724A/en not_active Application Discontinuation
- 2005-12-08 KR KR1020077015589A patent/KR20070086977A/en not_active Application Discontinuation
- 2005-12-08 CA CA002589966A patent/CA2589966A1/en not_active Abandoned
-
2007
- 2007-06-07 IL IL183754A patent/IL183754A0/en unknown
- 2007-06-15 NO NO20073058A patent/NO20073058L/en not_active Application Discontinuation
- 2007-07-06 ZA ZA200705557A patent/ZA200705557B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW200634014A (en) | 2006-10-01 |
AU2005313002A1 (en) | 2006-06-15 |
MX2007006745A (en) | 2007-07-09 |
KR20070086977A (en) | 2007-08-27 |
JP2008522967A (en) | 2008-07-03 |
IL183754A0 (en) | 2007-09-20 |
ZA200705557B (en) | 2008-09-25 |
BRPI0518610A2 (en) | 2008-11-25 |
WO2006061791A2 (en) | 2006-06-15 |
NO20073058L (en) | 2007-07-04 |
CN101072776A (en) | 2007-11-14 |
RU2007125724A (en) | 2009-01-20 |
AR052263A1 (en) | 2007-03-07 |
WO2006061791A3 (en) | 2006-08-10 |
EP1824851A2 (en) | 2007-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7915259B2 (en) | Diazabicyclononene derivatives and use thereof | |
RU2425032C2 (en) | Secondary amines as renin inhibitors | |
AU2003284188B2 (en) | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity | |
US20100324052A1 (en) | Novel piperidine carboxylic acid amine derivatives | |
KR20090008211A (en) | New amines | |
CA2589966A1 (en) | Novel diazabicyclononene derivative | |
JP2010527942A (en) | A new class of renin inhibitors | |
WO2006064484A1 (en) | Azabicyclononene derivatives as renin inhibitors | |
KR20080100382A (en) | Primary amines as renin inhibitors | |
JP2010510176A (en) | Renin inhibitor | |
KR20060015546A (en) | Tropane derivatives and their use as ace inhibitors | |
WO2007049224A1 (en) | Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives | |
WO2006021403A1 (en) | Bicyclononene derivatives | |
US20080103152A1 (en) | Novel Diazabicyclononene Derivative | |
WO2006059304A2 (en) | Novel lactame derivatives as renin inhibitors | |
WO2006131884A2 (en) | Thiazole substituted diazabicyclononane or-nonene derivatives as renin inhibitors | |
WO2007034406A1 (en) | Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin | |
CA2217202A1 (en) | Novel heterocyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |